Skip to main content
Log in

Serum YKL-40 following resection for cerebral glioblastoma

  • Laboratory Investigation - Human/Animal Tissue
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

The lack of serum biomarkers for assessing the prognosis of patients with cerebral glioblastoma multiforme (GBM) prompted the present study in order to evaluate the significance of serum YKL-40 values in patients operated on for glioblastoma. An homogeneous population of 60 patients who underwent surgical removal of GBM underwent a standard treatment (surgery, radiotherapy, chemotherapy in the same schedule) and standard radiological monitoring (same MRI sequences at pre-defined stages). Serum YKL-40 levels (Quidel Corporation, San Diego, CA) were evaluated after dividing patients into two groups on the basis of the extent of resection (total or sub-total) according to the MRI results obtained within 48 h following surgery. YKL-40 serum values, significantly higher in GBM patients than in healthy subjects, were also higher among patients who had undergone subtotal resection than in patients who underwent extensive resection. The effect of YKL-40 on overall survival was analyzed by comparing the change in marker concentration occurring in the first postoperative week with the baseline value. A significant (P = 0.04) hazards ratio of 1.97 was found at multivariate analysis. A significant association with shorter outcome (median survival time, 76 days) was found in patients whose postoperative YKL-40 concentration increases higher than, or equal to, 100%; a 50% increase can still be considered a negative prognostic index. The evaluation of the biochemical marker YKL-40 might provide earlier and additional information to that obtained using traditional factors and be a further aid in establishing the prognosis of GBM patients who have undergone surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453–461

    Article  PubMed  Google Scholar 

  2. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492–507

    Article  PubMed  CAS  Google Scholar 

  3. Tanwar MK, Gilbert MR, Holland EC (2002) Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 62:4364–4368

    PubMed  CAS  Google Scholar 

  4. Nutt CL, Betensky RA, Brower MA et al (2005) YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res 11:2258–2264

    Article  PubMed  CAS  Google Scholar 

  5. Nigro JM, Misra A, Zhang L et al (2005) Integrated array comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 65:1678–1686

    Article  PubMed  CAS  Google Scholar 

  6. Johansen JS, Christensen IJ, Riisbro R, Greenall M, Han C, Price PA, Smith K, Brunner N, Harris AL (2003) High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast Cancer Res Treat 80:15–21

    Article  PubMed  CAS  Google Scholar 

  7. Johansen JS, Drivsholm L, Price PA, Christensen IJ (2004) High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer 46:333–340

    Article  PubMed  Google Scholar 

  8. Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA et al (2006) YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 12:5698–5704

    Article  PubMed  CAS  Google Scholar 

  9. Pelloski CE, Mahajan A, Maor M et al (2005) YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res 11:3326–3334

    Article  PubMed  CAS  Google Scholar 

  10. Shah GD, Kesari S, Xu R et al (2006) Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro-oncology 8:38–46

    Article  PubMed  Google Scholar 

  11. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  12. Rees J (2003) Advances in magnetic resonance imaging of brain tumours. Curr Opin Neurol 16:643–650

    Article  PubMed  Google Scholar 

  13. Hogdall EVS, Johansen JS, Kjaer SK, Price PA, Blaakjaer J, Hogdall CK (2000) Stability of YKL-40 concentration in blood samples. Scand J Clin Lab Invest 60:247–252

    Article  PubMed  CAS  Google Scholar 

  14. Junker N, Johansen JS, Anderson CB, Kristjansen PEG (2005) Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer 48:223–231

    Article  PubMed  Google Scholar 

  15. Shostak K, Dmitrenko V, Labunskyy V et al (2003) HC gp-39 gene is up-regulated in glioblastomas. Cancer Lett 198:203–210

    Article  PubMed  CAS  Google Scholar 

  16. Johansen JS, Baslund B, Garbarsch C et al (1999) YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Arthr Rheum 42:2624–2630

    Article  CAS  Google Scholar 

  17. Park CK, Lee SH, Han JH et al (2009) Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy. BMC Cancer 9:450

    Article  PubMed  Google Scholar 

  18. Johansen JS, Bojesen SE, Tybjaerg-Hansen A et al (2010) Plasma YKL-40 and total and disease-specific mortality in the general population. Clin Chem 56:1580–1591

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Daniela Bernardi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bernardi, D., Padoan, A., Ballin, A. et al. Serum YKL-40 following resection for cerebral glioblastoma. J Neurooncol 107, 299–305 (2012). https://doi.org/10.1007/s11060-011-0762-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-011-0762-7

Keywords

Navigation